Biosimilar Red Tape Elimination Act
Summary
What This Bill Does
The Biosimilar Red Tape Elimination Act removes the separate statutory showing for interchangeability and deems a biosimilar interchangeable when licensed. Products licensed before the transition date become interchangeable 60 days after enactment. If another product tied to the same reference biologic has an unexpired first-interchangeable exclusivity period, the new deemed status waits until that period ends, and existing exclusivity is preserved for its remaining duration. Conforming changes remove separate interchangeability supplements and terminology, revise biosimilar pediatric-treatment rules, and align related statutes. Unlike the introduced version's mandatory 18-month guidance schedule, the final text merely authorizes HHS to issue or revise biosimilarity guidance, including information for device components of combination products, and says guidance timing cannot block application review.
Who Benefits and How
New and existing biosimilar sponsors gain automatic interchangeability without a separate application supplement, reducing regulatory cost and pharmacy-substitution barriers. Patients, employers, insurers, and public health programs may benefit from faster biosimilar competition and lower biologic spending. Existing first-interchangeable sponsors retain the remainder of earned exclusivity.
Who Bears the Burden and How
Reference biologic manufacturers face stronger substitution and price competition. FDA must implement broad conforming statutory changes even though the final bill does not impose a guidance deadline. Pharmacies, prescribers, payers, and state substitution systems must adapt to a much larger set of products deemed interchangeable. Pediatric reviewers must apply the revised active-ingredient rule.
Key Provisions
- Establishes automatic interchangeability for section 351(k) biosimilars.
- Extends deemed interchangeability to previously licensed products after a 60-day transition.
- Protects unexpired first-interchangeable exclusivity for its remaining term.
- Repeals separate interchangeability supplements and related statutory references.
- Authorizes optional FDA biosimilarity guidance without delaying application review.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Makes biosimilars licensed under section 351(k) automatically interchangeable with their reference products while preserving unexpired first-interchangeable exclusivity.
Key Policy Areas
Healthcare, Drug Competition, Biotechnology
Primary Purpose
Makes biosimilars licensed under section 351(k) automatically interchangeable with their reference products while preserving unexpired first-interchangeable exclusivity.
Policy Domains
Biosimilar Red Tape Elimination Act
Identified Gains
- Biosimilar sponsors
- Patients using biologic medicines
- Health insurers
- Employers purchasing health coverage
- Existing first-interchangeable sponsors
Identified Costs
- Reference biologic manufacturers
- FDA biosimilar program staff
- Pharmacy substitution systems
- Pediatric drug-review staff
Sponsors
Legislative Progress
ReportedPlaced on Senate Legislative Calendar under General Orders. Calendar No. …
Committee on Health, Education, Labor, and Pensions. Reported by Senator …
Reported by Mr. Cassidy, with an amendment
Committee on Health, Education, Labor, and Pensions. Ordered to be …
Mr. Lee (for himself, Mr. Luján, Mr. Paul, and Ms. …
Read twice and referred to the Committee on Health, Education, …
Introduced in Senate
Mr. Lee (for himself, Mr. Luján, Mr. Paul, Ms. Hassan, …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Biosimilar sponsors, Existing first-interchangeable sponsors, Health insurers
Positive-direction: Biosimilar sponsors, Existing first-interchangeable sponsors, Health insurers
Negative-direction: Reference biologic manufacturers
FDA biosimilar guidance staff, FDA biosimilar program staff, Federal legislative records staff
FDA biosimilar guidance staff faces effects in multiple directions
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "entrants"
- → Biosimilar biological product sponsors
- "regulator"
- → Secretary of Health and Human Services acting through FDA
- "incumbents"
- → Reference biologic manufacturers
- "purchasers"
- → Patients, employers, insurers, and public health programs
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology